SCHEMBL2921088

SCHEMBL2921088

C[C@@H]1CCC[C@H](C)N1Cc1ccc2cc(NC(=O)N3CCC(c4ccc(Cl)cc4)CC3)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.59
HTR2C P28335 1/20 0.59
MAPT P10636 7/20 0.48
TP53 P04637 6/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 3/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
NAMPT P43490 1/20 0.45
ALOX5 P09917 1/20 0.44
STAT1 P42224 1/20 0.44
NLRP3 Q96P20 1/20 0.43
FAAH O00519 1/20 0.43
HTT P42858 1/20 0.42
CCR1 P32246 1/20 0.42
CHRM4 P08173 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2921092 1.00 MCHR1 (0.59) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL13177223 0.91 MCHR1 (0.59) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL13177425 0.90 MCHR1 (0.63) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL2925998 0.87 MCHR1 (0.77) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL2926868 0.86 MCHR1 (0.59) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL2926870 0.86 MCHR1 (0.59) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL6305313 0.86 MCHR1 (0.70) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL2925899 0.86 MCHR1 (0.75) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL6304597 0.84 MCHR1 (0.65) MCHR1HTR2CMAPTTP53SMN1; SMN2
SCHEMBL6314243 0.84 MCHR1 (0.65) MCHR1HTR2CMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885MAPT 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.